A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Merck Sharp & Dohme LLC
Qilu Pharmaceutical Co., Ltd.
Bio-Cancer Treatment International Limited
Hoffmann-La Roche
Sanofi
Pfizer
PhytoCeutica